Business Context and Reporting Period
Company: Nu Skin Enterprises, Inc. (NUS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: Nu Skin develops and distributes premium beauty and wellness solutions via a direct selling channel in nearly 50 markets. The company operates two primary segments: the core Nu Skin business (beauty and wellness products) and Rhyz Inc., a strategic investment arm focused on consumer, technology, and manufacturing companies.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $1.49 billion | $1.73 billion |
| Net Income (Loss) | $160.2 million | $(146.6) million |
| Diluted EPS | $3.18 | $(2.95) |
| Gross Margin | 69.4% | 68.2% |
| Operating Income | $65.8 million | $(151.6) million |
| Cash from Operations | $80.3 million | $111.7 million |
| Cash and Equivalents (Year End) | $239.8 million | $198.0 million |
| Total Debt Outstanding | $225.0 million | $395.0 million |
Note: 2025 results include a pre-tax gain of $176.2 million from the sale of the Mavely business.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 14% year-over-year, driven by macroeconomic pressures, reduced consumer spending, and the divestiture of the Mavely business (which contributed $69.6 million in 2024 revenue).
- Profitability Turnaround: The company returned to net profitability ($160.2 million) from a net loss in 2024, primarily due to the gain on the sale of Mavely and reduced restructuring/impairment charges compared to the prior year.
- Segment Performance:
- Core Nu Skin: Revenue declined 12.7% to $1.26 billion. Significant declines were observed in South Korea (-20.5%), Mainland China (-16.9%), and Southeast Asia/Pacific (-14.3%).
- Rhyz Other: Revenue plummeted 79.1% due to the Mavely sale, though the LifeDNA subsidiary saw 188% revenue growth.
- Manufacturing: Revenue increased 2.2%.
- Sales Force Metrics: As of December 31, 2025, Customers decreased 10%, Paid Affiliates decreased 11%, and Sales Leaders decreased 19% compared to 2024.
- Debt Reduction: The company utilized proceeds from the Mavely sale to pay down $170 million in debt, reducing total outstanding borrowings significantly.
Guidance, Outlook, and Risks
- Strategic Initiatives: Management is focusing on business model optimization, the rollout of the Prysm iO wellness device (full commercial launch expected in 2026), and market expansion into India (anticipated full opening in late 2026).
- Financial Outlook: The company anticipates an effective tax rate of 28-36% for 2026. Capital expenditures are estimated at $40-60 million for 2026.
- Key Risks:
- Regulatory Scrutiny: Ongoing challenges in Mainland China regarding direct selling regulations and product registration. Increased FTC scrutiny on earnings claims and multi-level marketing practices in the U.S.
- Market Conditions: Continued macroeconomic headwinds, inflation, and currency fluctuations impacting international revenue.
- Product Liability & Claims: Risks associated with product claims, particularly regarding structure/function claims for cosmetics and supplements, and potential reclassification of devices as medical devices.
- Cybersecurity: Exposure to data breaches and cyberattacks, with the company self-insuring against these risks.
Investor Verification Checklist
- Sustainability of Earnings: Verify the extent to which 2025 net income was driven by the one-time $176.2 million gain on the Mavely sale versus core operational improvements.
- Mainland China Exposure: Assess the impact of continued regulatory restrictions and the 16.9% revenue decline in Mainland China on future growth prospects.
- Sales Force Retention: Monitor the 19% decline in Sales Leaders and the effectiveness of new sales compensation plans in stabilizing the distribution network.
- Prysm iO Adoption: Evaluate the commercial success of the Prysm iO device launch in 2026 as a driver for future subscription revenue.
- Debt Covenants: Confirm continued compliance with leverage and interest coverage ratios under the Credit Agreement, especially given the refinancing planned for the first half of 2026.